These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23934470)

  • 1. A high chromogranin A: Is it always a tumor?
    Turhan Iyidir O; Cimen AR; Değertekin CK; Baloş Törüner F; Cakır N; Arslan M
    Turk J Gastroenterol; 2013; 24(2):186-7. PubMed ID: 23934470
    [No Abstract]   [Full Text] [Related]  

  • 2. The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders.
    Savarino E; De Cassan C; Bodini G; Furnari M; de Bortoli N; Savarino V
    J Gastroenterol; 2014 Sep; 49(9):1362-3. PubMed ID: 24972668
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
    Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
    Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebound hypersecretion after inhibition of gastric acid secretion.
    Qvigstad G; Waldum H
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):202-8. PubMed ID: 15125689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sticky Palms Following Use of Proton-Pump Inhibitors.
    Alkeraye S; Baclet Y; Delaporte E
    JAMA Dermatol; 2016 Jun; 152(6):722-3. PubMed ID: 26962767
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to the letter by E. Savarino et al. regarding "The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders".
    Kinoshita Y; Miwa H; Sanada K; Miyata K; Haruma K
    J Gastroenterol; 2014 Sep; 49(9):1364-5. PubMed ID: 24974095
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
    Takenaka R; Okada H; Kawano S; Komazawa Y; Yoshinaga F; Nagata S; Inoue M; Komatsu H; Onogawa S; Kushiyama Y; Mukai S; Todo H; Okanobu H; Manabe N; Tanaka S; Haruma K; Kinoshita Y
    World J Gastroenterol; 2016 Jun; 22(23):5430-5. PubMed ID: 27340360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric carcinoids after long-term use of a proton pump inhibitor.
    Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
    Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
    Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
    Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease.
    Xiong W; Zhang QS; Zhao W; Ding W; Liu JM; Zhao YF
    Int J Exp Pathol; 2016 Apr; 97(2):107-13. PubMed ID: 27135904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.
    Miwa H; Haruma K; Sakamoto S; Sanada K; Hiroi S; Kinoshita Y
    J Gastroenterol Hepatol; 2015 May; 30(5):834-41. PubMed ID: 25559435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
    Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
    Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
    Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
    Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
    Ter Arkh; 2012; 84(2):16-21. PubMed ID: 22715656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia.
    Hassall E; Owen D; Kerr W; Sturby T; Richardson P; El-Serag H
    Aliment Pharmacol Ther; 2011 Apr; 33(7):829-36. PubMed ID: 21320136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy.
    Igaz P; Müllner K; Hargitai B; Igaz I; Tömböl Z; Rácz K; Tulassay Z
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):805-6. PubMed ID: 17608816
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
    Bordin DS; Masharova AA
    Eksp Klin Gastroenterol; 2008; (5):85-90. PubMed ID: 19145922
    [No Abstract]   [Full Text] [Related]  

  • 19. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
    Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
    J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is proton pump inhibitors unresponsiveness in gastroesophageal reflux disease? How should these cases be managed?
    Çelebi A; Yılmaz H
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S71-S72. PubMed ID: 29199173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.